Konstantinos Tsionos

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.

Meletios Α. Dimopoulos, Efstathios Kastritis, Ioannis Melakopoulos et al. · PubMed · 2006 · 341 citations

Medicine, Oral Pathology, Bone Metabolism +10

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

Evangelos Terpos, Efstathios Kastritis, D Heath et al. · Leukemia · 2008 · 115 citations

Medicine, Hematology, Pharmacology +17

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

Evangelos Terpos, John Palermos, Konstantinos Tsionos et al. · European Journal Of Haematology · 2000 · 71 citations

Medicine, Pharmacology, Pharmacotherapy +16

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

Evangelos Terpos, Eirini Katodritou, E. Tsiftsakis et al. · Haematologica · 2009 · 69 citations · Full text

Medicine, Oncology, Pharmacology +14

“Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group

Eirini Katodritou, Chrysanthi Vadikolia, Chrysavgi Lalagianni et al. · Annals of Hematology · 2013 · 39 citations

Medicine, Pharmacology, Pharmacotherapy +16